Skip to main content

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Active, not recruiting · Phase 1, Phase 2 · NCT04145622

Conditions: Advanced Solid Tumor, Malignant Solid Tumor

At a glance

Research payments reported, 2025
$178,636
U.S. investigators named
2
Sites paid
2
Planned or actual enrollment
247

About the trial

Sponsor
Daiichi Sankyo (with Merck Sharp & Dohme LLC)
Tested
Ifinatamab deruxtecan (I-DXd) (drug)
Dates
Started 2019-11-03; completion 2029-10-31
Results posted
Not yet

This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability and to determine the maximum tolerated dose and the recommended dose for expansion of ifinatamab deruxtecan (I-DXd). * Dose Expansion Part: To investigate the safety, tolerability and antitumor activity of I-DXd when administered as a single agent. This study is expected to last approximately 5 years from the time the first participant is enrolled to the time the last participant is off the stud…

From ClinicalTrials.gov, last updated 2026-10-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Daiichi Sankyo Inc. reported $178,636 in research payments for this study in 2025 (7 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.